Refractory Erdheim-Chester disease
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB08881 | Vemurafenib | Vemurafenib is a BRAF enzyme inhibitor developed by Plexxikon and Genentech for the treatment of late-stage melanoma. The cobas® 4800 BRAF B600 mutation test provided by Roche Molecular Systems is the diagnostic test to confirm eligibility for treatment. FDA approved on August 17, 2011 under the company Hoffmann La Roche. |
| Drug | Drug Name | Phase | Status | Count |
|---|